| chronic pain (diagnosis)
Butrans vs Prialt
Side-by-side clinical, coverage, and cost comparison for chronic pain (diagnosis).Deep comparison between: Butrans vs Prialt with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPrialt has a higher rate of injection site reactions vs Butrans based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Prialt but not Butrans, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Butrans
Prialt
At A Glance
Transdermal patch
Every 7 days
Partial mu-opioid agonist
Intrathecal infusion
Continuous infusion
N-type calcium channel blocker
Indications
- chronic pain (diagnosis)
- chronic pain (diagnosis)
Dosing
chronic pain (diagnosis) For opioid-naive patients, initiate with BUTRANS 5 mcg/hour transdermal patch worn for 7 days; for patients on 30-80 mg/day oral morphine equivalents, taper current opioid to <=30 mg/day then initiate at 10 mcg/hour; maximum dose is 20 mcg/hour (one system); titrate no more frequently than every 72 hours in increments of 5, 7.5, or 10 mcg/hour.
chronic pain (diagnosis) Initiate at no more than 2.4 mcg/day (0.1 mcg/hr) intrathecally; titrate by up to 2.4 mcg/day at intervals no more than 2-3 times per week; maximum recommended dose 19.2 mcg/day (0.8 mcg/hr).
Contraindications
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity (e.g., anaphylaxis) to buprenorphine or any excipient
- Known hypersensitivity to ziconotide or any formulation component
- Any concomitant treatment or medical condition rendering intrathecal administration hazardous
- Infection at the microinfusion injection site
- Uncontrolled bleeding diathesis
- Spinal canal obstruction that impairs circulation of CSF
- Pre-existing history of psychosis
Adverse Reactions
Most common (>=5%) Nausea, headache, application site pruritus, dizziness, constipation, somnolence, vomiting, application site erythema, dry mouth, application site rash
Serious Life-threatening respiratory depression, addiction/abuse/misuse, interactions with CNS depressants, neonatal opioid withdrawal syndrome, QTc prolongation, anaphylaxis/allergic reactions, hepatotoxicity, seizures, adrenal insufficiency, severe hypotension
Postmarketing Serotonin syndrome, adrenal insufficiency, anaphylaxis, androgen deficiency, hyperalgesia and allodynia, hypoglycemia, opioid-induced esophageal dysfunction
Most common (>=25%) dizziness, nausea, confusional state, nystagmus
Serious acute renal failure, atrial fibrillation, cerebrovascular accident, sepsis, meningitis, psychotic disorder, suicidal ideation, respiratory distress, rhabdomyolysis, fatal aspiration pneumonia, suicide attempt
Postmarketing hypersensitivity reactions including angioedema, bullous dermatitis, skin ulcers, skin exfoliation, burning skin sensation
Pharmacology
Buprenorphine is a partial agonist at the mu-opioid receptor, an antagonist at kappa-opioid receptors, an agonist at delta-opioid receptors, and a partial agonist at ORL-1 (nociceptin) receptors; it produces analgesia and respiratory depression via central opioid receptor modulation, with pharmacodynamic effects including CNS depression, reduced GI motility, and peripheral vasodilation.
Ziconotide is an N-type calcium channel blocker; it binds to N-type calcium channels on primary nociceptive afferent nerves in the dorsal horn of the spinal cord, blocking excitatory neurotransmitter release from afferent nerve terminals and producing antinociception.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Butrans
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (10/12)
Prialt
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (6/12) · Qty limit (0/12)
UnitedHealthcare
Butrans
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (6/8)
Prialt
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Butrans
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Prialt
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Butrans.
$20/fillfill
Prialt Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ButransView full Butrans profile
PrialtView full Prialt profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.